BioMed Research International / 2014 / Article / Tab 1 / Research Article
Synthesis and Preclinical Characterization of [18 F]FPBZA: A Novel PET Probe for Melanoma Table 1 Biodistribution of
18 F
FPBZA in C57BL/6 mice bearing either B16F0 tumor or inflammation and Balb/c nude mice bearing A375 tumor after intravenous injection. Mice were injected with 3.7 MBq of
18 F
FPBZA through lateral tail vein. Results were expressed as the percentage of injection dose per gram of organ (%ID/g) (
; mean ± SD).
B16F0 tumor A375 tumor Inflammation 30 min 60 min 120 min 120 min 120 min Blood 3.78 ± 0.41 2.91 ± 0.18 2.17 ± 0.10 2.48 ± 0.08 2.14 ± 0.22 Heart 3.30 ± 0.42 2.90 ± 0.23 2.26 ± 0.15 2.51 ± 0.21 2.30 ± 0.31 Lung 3.07 ± 0.42 2.37 ± 0.19 1.05 ± 0.32 1.57 ± 0.19 1.19 ± 0.06 Liver 3.43 ± 0.27 2.67 ± 0.25 1.74 ± 0.25 2.04 ± 0.27 1.78 ± 0.21 Stomach 3.17 ± 0.81 2.11 ± 0.58 1.28 ± 0.13 1.48 ± 0.45 1.31 ± 0.07 Si 3.98 ± 1.05 2.45 ± 0.38 1.32 ± 0.19 1.94 ± 0.09 1.48 ± 0.13 Li 4.38 ± 0.58 2.33 ± 0.50 2.41 ± 0.38 2.67 ± 0.19 2.13 ± 0.69 Spleen 3.13 ± 0.52 2.37 ± 0.49 1.42 ± 0.25 1.61 ± 0.58 1.76 ± 0.15 Pancreas 3.09 ± 0.67 2.09 ± 0.31 1.08 ± 0.07 1.07 ± 0.32 1.30 ± 0.26 Muscle 2.83 ± 0.46 1.87 ± 0.21 1.16 ± 0.09 1.26 ± 0.02 1.28 ± 0.07 Bone 2.68 ± 0.38 2.93 ± 0.40 3.21 ± 0.16 3.53 ± 0.10 3.48 ± 0.85 Tumor 10.37 ± 1.13 8.31 ± 1.00 7.81 ± 0.82 3.00 ± 0.71 Kidney 4.92 ± 0.74 3.44 ± 0.44 2.00 ± 0.12 1.97 ± 0.59 2.27 ± 0.79 Eyeball 12.13 ± 0.94 9.74 ± 1.32 7.69 ± 1.56 2.91 ± 0.45 6.55 ± 0.45 Brain 2.24 ± 0.23 2.07 ± 0.15 1.49 ± 0.21 1.89 ± 0.37 1.64 ± 0.16 Inflammation 1.67 ± 0.56 Uptake ratio Tumor-To-Muscle 3.72 ± 0.53 4.47 ± 0.58 6.60 ± 1.00 2.72 ± 0.05 Tumor-To-Liver 2.90 ± 0.23 3.12 ± 0.33 4.49 ± 0.60 1.70 ± 0.24 Tumor-To-Blood 2.52 ± 0.07 2.86 ± 0.34 3.52 ± 0.51 1.38 ± 0.04 Tumor-To-Brain 4.54 ± 0.20 4.03 ± 0.43 5.19 ± 0.93 1.72 ± 0.03 Tumor-to-lung 3.43 ± 0.56 3.53 ± 0.51 9.01 ± 4.85 2.27 ± 0.32